| Size | Price | |
|---|---|---|
| 250mg | ||
| 500mg | ||
| Other Sizes |
| Targets |
Cefodizime sodium targets bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the transpeptidase enzyme and disrupting peptidoglycan cross-linking, leading to bacterial cell lysis and death.
|
|---|---|
| ln Vitro |
Salmonella, Yersinia enterocolitica, Escherichia coli, Morganella spp., Proteus mirabilis, Proteus vulgaris, Shigella sonnei, and Klebsiella pneumoniae are among the Enterobacteriaceae that are resistant to cefodizim in vitro. Citrobacter freundii and Serratia marcescens are two Citrobacter species against which cefodizime has varying degrees of marginal inhibitory action. Other Gram-negative bacteria, such as Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae, are inhibited by cefodizime [1]. The bactericidal antibiotic cefodizime has a strong affinity for Escherichia coli's penicillin-binding proteins 1A/B, 2, and 3. The lowest inhibitory concentration and the in vitro concentrations at which cefodizime is bactericidal against sensitive strains of Gram-positive and Gram-negative bacteria are often comparable [1].
In vitro studies demonstrate that Cefodizime sodium has broad-spectrum antibacterial activity against susceptible bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, and various Gram-negative organisms, with stability against most beta-lactamases. |
| ln Vivo |
When mice were given a single subcutaneous dose of 50 mg/kg of cephalosporins, cefuroxime, or cefazolin, eight hours later, the activity of cefodizime was higher than that of cefoperazone, ceftazidime, and cefotaxime in an experimentally induced respiratory tract infection caused by Klebsiella pneumoniae. But unlike these cephalosporins, cefodizime has a noticeable bactericidal effect for a minimum of 48 hours following a single injection. Within 48 hours, 50% of the mice had completely cleared their lungs of all germs, even though cefodizime was no longer visible in their serum [1].
In vivo, Cefodizime sodium is used clinically for the treatment of infections caused by susceptible bacteria, including pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infections, gonococcal urethritis, cholecystitis, and cholangitis; it also has immunomodulatory properties and has been used as an immunostimulant in cancer adjunctive therapy. |
| Enzyme Assay |
The in vitro antimicrobial susceptibility assay involves incubating Cefodizime sodium with bacterial isolates in broth or agar medium, determining the minimum inhibitory concentration (MIC) by broth microdilution or disk diffusion methods according to CLSI guidelines, and measuring bacterial growth inhibition.
|
| Cell Assay |
In vitro cell culture studies for immunomodulatory effects utilize immune cells (e.g., macrophages, lymphocytes) treated with Cefodizime sodium, assessing cytokine production by ELISA, phagocytic activity by flow cytometry, and immune cell proliferation by [3H]-thymidine incorporation or CFSE dilution.
|
| Animal Protocol |
In vivo animal models for evaluating Cefodizime sodium include murine models of bacterial infection (e.g., pneumonia, sepsis), where the compound is administered via parenteral routes, with bacterial load assessed in target organs, survival outcomes monitored, and immunomodulatory effects evaluated by measuring immune cell populations and cytokine levels.
|
| ADME/Pharmacokinetics |
Cefodizime sodium has a molecular formula C20H18N6Na2O7S4 and molecular weight 628.63 g/mol; it is a parenteral antibiotic typically stored at 2-8°C, with purity ≥96% (HPLC), and is reconstituted in sterile water or saline for injection.
|
| Toxicity/Toxicokinetics |
Toxicological data indicate that Cefodizime sodium is generally well-tolerated, with common adverse effects including gastrointestinal disturbances, hypersensitivity reactions, and injection site reactions; it is contraindicated in patients with known allergy to cephalosporins or penicillins.
|
| References |
|
| Additional Infomation |
Cefodizime sodium is a cephalosporin. Cefodizime sodium is the sodium salt form of cephalosporin, a third-generation aminothiazole cephalosporin used for parenteral administration. Cefodizime has broad-spectrum antibacterial activity and is stable against most β-lactamases.
Cefodizime sodium is an approved parenteral cephalosporin antibiotic used clinically for the treatment of bacterial infections; it has been marketed in various countries and is also used as an immunostimulant in cancer therapy adjunctively, though its use has been partially supplanted by newer cephalosporins with broader spectra. |
| Molecular Formula |
C20H18N6NA2O7S4
|
|---|---|
| Molecular Weight |
628.6325
|
| Exact Mass |
627.991
|
| CAS # |
86329-79-5
|
| Related CAS # |
Cefodizime;69739-16-8
|
| PubChem CID |
9852176
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
39
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(SC(=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-])CC(=O)[O-].[Na+].[Na+]
|
| InChi Key |
WBOBLQIRACJNPA-AEKYOGSZSA-L
|
| InChi Code |
InChI=1S/C20H20N6O7S4.2Na/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9;;/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32);;/q;2*+1/p-2/b25-12-;;/t13-,17-;;/m1../s1
|
| Chemical Name |
disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxylatomethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~159.08 mM)
DMSO : ~62.5 mg/mL (~99.42 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 100 mg/mL (159.08 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5908 mL | 7.9538 mL | 15.9076 mL | |
| 5 mM | 0.3182 mL | 1.5908 mL | 3.1815 mL | |
| 10 mM | 0.1591 mL | 0.7954 mL | 1.5908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
